Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Dosing of Ipilimumab and Nivolumab in Metastatic Melanoma
NCT03122522Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2017
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate at 6 weeks. Started Apr 2017; status: active, not recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03122522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122522.